Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Supernus Pharmaceuticals and United Therapeutics have signed a definitive licensing agreement for the development of UT-15C, United Therapeutics' oral prostacyclin analog.
Subscribe to our email newsletter
UT-15C is an oral sustained release formulation of treprostinil, the active ingredient in United Therapeutics’ Remodulin, which is currently marketed for subcutaneous and intravenous treatment of pulmonary arterial hypertension.
Under the license agreement, Supernus will receive milestone payments and royalties from United Therapeutics based on the sales of UT-15C. Commercial scale-up activities for UT-15C are ongoing and United Therapeutics has recently started late stage multi-national placebo-controlled clinical studies for the treatment of pulmonary arterial hypertension.
The licensing agreement contemplates United Therapeutics’ development of UT-15C for additional indications.
“Our decision to work with Supernus was based on Supernus’ superior development experience with sustained release formulations and their innovative patented osmotic technology,” said Dr David Mottolavice president of product development at United Therapeutics. “Our collaboration with Supernus on UT-15C moves us closer to our goal of providing patients the convenience of an oral prostacyclin agent that is administered twice per day.”